Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy

详细信息	查看全文 | 推荐本文 |

• 作者：Suzuki ; Katsunori ; Souda ; Satoshi ; Ikarashi ; Tomoo ; Kaneko ; Susumu ; Nakagawa ; Osamu ; Aizawa ; Yoshifusa
• 关键词：Diabetic nephropathy ; Valsartan ; Type 2 diabetes
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2002
• 期刊代码：78_01688227
• 类别：med
• 出版时间：September, 2002
• 卷：57
• 期：3
• 页码：179-183
• 文件大小：95.9 K

摘要

It is unknown whether the angiotensin receptor antagonist valsartan exerts a renoprotective effect on patients with type 2 diabetes and diabetic nephropathy independent of its hypotensive effects. Forty patients with type 2 diabetes participated in this study. All patients received valsartan 40 mg, a dose with no clinical effect on blood pressure levels. Blood pressure, urinary albumin excretion (UAE), and creatinine clearance were determined at baseline and at the end of the 6-month treatment period. Antihypertensive and/or antidiabetic drugs, including insulin, were permitted throughout the study. After 6 months of valsartan therapy, mean UAE decreased from 86.8±196 to 46.9±97 μg/min (n